
Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year
1/07/2026 | 32 mins.
He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026
12/30/2025 | 33 mins.
He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza
12/29/2025 | 45 mins.
We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."
12/12/2025 | 20 mins.
Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization
12/11/2025 | 13 mins.
CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.



BiotechTV - News